Treatment experience of coronavirus infection associated with SARS-CoV-2 in patients with acute myeloid leukemia in the older age group
L. T. Shimanovskaya,
E. N. Misyurina,
E. A. Baryakh,
E. I. Zhelnova,
K. V. Yatskov,
T. S. Chudnova,
A. B. Makeshova,
M. A. Mingalimov,
D. D. Ivanova,
O. L. Kochneva,
E. N. Zotina,
T. N. Tolstykh,
E. Yu. Grishina,
D. E. Gagloeva,
Yu. Yu. Polyakov,
V. N. Yakimets,
A. I. Koneva https://doi.org/10.17650/1818-8346-2023-18-4(Suppl)-53-63
Abstract
Aim. To study the course of COVID-19 (COronaVIrus Disease 2019) in elderly patients with acute myeloid leukemia (AML), to analyze risk factors for unfavorable outcome.
Materials and methods. The paper presents our own experience in the treatment of elderly (age ≥65 years) patients with AML and concomitant coronavirus infection in the hematology departments of City Clinical Hospital No. 52 (Moscow) from March 2020 to June 2022. The diagnosis of COVID-19 was considered confirmed based on a positive result of the polymerase chain reaction of an oropharyngeal and nasopharyngeal swab for SARS-CoV-2 and/or a typical radiological picture on a computed tomogram of the lungs.
Results. An analysis of clinical, laboratory and instrumental data of 59 patients (30 (51 %) men, 29 (49 %) women) with AML and COVID-19 was carried out. All patients were treated for COVID-19 in accordance with the Temporary guidelines “Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)” of the Russian Ministry of Health. Median age was 71 (65-91) years. AML was first verified in 27 % of hospitalized patients; 12 % were in remission of the disease. A month before hospitalization, 36 % of patients received antitumor therapy, and 19 % of patients had refractory AML. 17 % of hospitalized patients received antitumor therapy with cytarabine in small doses for vital indications. Death was recorded in 64 % of cases, in 24 % the cause of death was severe COVID-19. The unfavorable outcome was influenced by addition of secondary bacterial flora, refractory AML course and elderly age of patients.
Conclusion. Pre-exposure prophylaxis with monoclonal antibodies and vaccination of patients may be the main methods of preventing infection and severe course of COVID-19.
About the Authors
L. T. Shimanovskaya
City Clinical Hospital No. 52, Moscow Healthcare Department
Russian Federation
Russian Federation
Liliya T. Shimanovskaya.
3 Pekhotnaya St., Moscow 123182
E. N. Misyurina
City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182; Build. 2, 8 Trubetskaya St., Moscow 119991
E. A. Baryakh
City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University); Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182; Build. 2, 8 Trubetskaya St., Moscow 119991; Build. 1, 2 / 1 Barrikadnaya St., Moscow 125993; 1 Ostrovityanova St., Moscow 117997
E. I. Zhelnova
City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182; Build. 2, 8 Trubetskaya St., Moscow 119991
K. V. Yatskov
City Clinical Hospital No. 52, Moscow Healthcare Department
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182
T. S. Chudnova
City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182; Build. 2, 8 Trubetskaya St., Moscow 119991
A. B. Makeshova
City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182; Build. 2, 8 Trubetskaya St., Moscow 119991
M. A. Mingalimov
City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182; Build. 2, 8 Trubetskaya St., Moscow 119991
D. D. Ivanova
City Clinical Hospital No. 52, Moscow Healthcare Department
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182
O. L. Kochneva
City Clinical Hospital No. 52, Moscow Healthcare Department
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182
E. N. Zotina
City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182; Build. 2, 8 Trubetskaya St., Moscow 119991
T. N. Tolstykh
City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182; Build. 2, 8 Trubetskaya St., Moscow 119991
E. Yu. Grishina
City Clinical Hospital No. 52, Moscow Healthcare Department
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182
D. E. Gagloeva
City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182; Build. 2, 8 Trubetskaya St., Moscow 119991
Yu. Yu. Polyakov
City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182; Build. 2, 8 Trubetskaya St., Moscow 119991
V. N. Yakimets
City Clinical Hospital No. 52, Moscow Healthcare Department
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182
A. I. Koneva
City Clinical Hospital No. 52, Moscow Healthcare Department
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182
References
1. Shallis R.M., Wang R., Davidoff A. et al. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev 2019;36:70-87. DOI: 10.1016/j.blre.2019.04.005
2. Mackenzie J.S., Smith D.W. COVID-19 — a novel zoonotic disease: a review of the disease, the virus, and public health measures. Asia Pac J Public Health 2020;32(4):145-53. DOI: 10.1177/1010539520931326
3. Kahathuduwa C., Dhanasekara C., Chin S.H. Case fatality rate in COVID-19: a systematic review and meta-analysis. J Prev Med J Pr 2021;30;62(2):311-20. DOI: 10.15167/2421-4248/jpmh2021.62.2.1627
4. World Health Organization. WHO Corona Virus (COVID-19) Dash Board. Available at: https://covid19.who.int (accessed on 17 June 2022).
5. Abate S.M., Ahmed Ali S., Mantfardo B. et al. Rate of intensive care unit admission and outcomes among patients with coronavirus: a systematic review and meta-analysis. PLoS One 2020;15:e0235653. DOI: 10.1371/journal.pone.0235653
6. Regalado-Artamendi I., Jimenez-Ubieto A., Hernandez-Rivas J.A. et al. Risk factors and mortality of COVID-19 in patients with lymphoma: a multicenter study. Hemasphere 2021;5(3):e538. DOI: 10.1097/HS9.0000000000000538
7. COVID-19 Lessons from Wuhan: Frequently Asked Questions [Internet]. Available at: https://www.hematology.org/covid-19/covid-19-lessons-from-wuhan (accessed on 16 June 2020).
8. He W., Chen L., Chen L. et al. COVID-19 in persons with hematological cancers. Leukemia 2020;34(6):1637-45. DOI: 10.1038/s41375-020-0836-7
9. Martm-Moro F., Marquet J., Piris M. et al. Survival study of hospitalised patients with concurrent COVID-19 and haematological malignancies. Br J Haematol 2020;190(1):16-20. DOI: 10.1111/bjh.16801
10. Marchesi F., Salmanton-Garda J., Emarah Z. et al. COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA). Haematologica 2023;108(1):22-33. DOI: 10.3324/haematol.2022.280847
11. Cai J., Sun W., Huang J. et al. Indirect virus transmission in cluster of COVID-19 cases, Wenzhou, China, 2020. Emerg Infect Dis 2020;26(6):1343-5. DOI: 10.3201/eid2606.200412
12. Hemmelgarn B.R., Manns B.J., Quan H. et al. Adapting the Charlson comorbidity index for use in patients with ESRD. Am J Kidney Dis 2003;42(1):125-32. DOI: 10.1016/s0272-6386(03)00415-3
13. Jensen M.D., Ryan D.H., Apovian C.M. et al. 2013 AHA/ACC/ TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation 2014;129(25 Suppl 2):102-38. DOI: 10.1161/01.cir.0000437739.71477.ee
Review
For citations:
Shimanovskaya L.T., Misyurina E.N., Baryakh E.A., Zhelnova E.I., Yatskov K.V., Chudnova T.S., Makeshova A.B., Mingalimov M.A., Ivanova D.D., Kochneva O.L., Zotina E.N., Tolstykh T.N., Grishina E.Yu., Gagloeva D.E., Polyakov Yu.Yu., Yakimets V.N., Koneva A.I. Treatment experience of coronavirus infection associated with SARS-CoV-2 in patients with acute myeloid leukemia in the older age group. Oncohematology. 2023;18(4):53-63. (In Russ.) https://doi.org/10.17650/1818-8346-2023-18-4(Suppl)-53-63
Views:
2252
Email this article 